Journey Medical Corporation (DERM)Healthcare | Drug Manufacturers - Specialty & Generic | Scottsdale, United States | NasdaqCM
7.47 USD
-0.06
(-0.797%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.56 +0.09 (1.205%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:23 a.m. EDT
The immediate catalyst is the August 12 earnings call regarding the expansion of the rosacea drug Emrosi to 150 million lives, which provides a tangible near-term tailwind. While the statistical forecast model shows low confidence and a flat prediction, the options market is aggressively pricing in a move higher, with call open interest concentrated well above the current price. Fundamentally, the company is in a turnaround phase; it has erased a multi-year decline with two consecutive years of double-digit growth and is now profitable on an operating basis, though still burning cash. The balance sheet is fragile with debt nearly matching cash, but the lack of a dividend and the speculative nature of the stock mean investors are betting on the pipeline, not income. The short-term rating is elevated due to the upcoming catalyst and options flow, but the long-term rating remains moderate because the path to profitability is still narrow and the stock carries significant execution risk. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.073231 |
| AutoTheta | 0.075379 |
| AutoARIMA | 0.084694 |
| AutoETS | 0.085022 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 3.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.262 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 79.532 |
| Revenue per Share | 2.552 |
| Market Cap | 210,836,240 |
| Forward P/E | -124.50 |
| Beta | 1.08 |
| Profit Margins | -8.95% |
| Website | https://journeymedicalcorp.com |
As of Aug. 22, 2026, 3:23 a.m. EDT: Speculators are positioning for a significant upside breakout, evidenced by heavy open interest in $10 calls for the August expiration compared to negligible put activity. Conversely, deep out-of-the-money puts ($2.50 strike) dominate the November and February expirations, suggesting a floor or a 'long gamma' strategy rather than a bearish bet. The massive implied volatility skew on the near-term ATM puts indicates fear of a gap down around the earnings announcement, while the call structure suggests a bullish thesis on the drug pipeline expansion.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.04915726 |
| Address1 | 9,237 East Via de Ventura Blvd. |
| Address2 | Suite 105 |
| All Time High | 10.2 |
| All Time Low | 1.02 |
| Ask | 7.49 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 183,100 |
| Average Daily Volume3 Month | 248,041 |
| Average Volume | 248,041 |
| Average Volume10Days | 183,100 |
| Beta | 1.084 |
| Bid | 5.4 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.161 |
| City | Scottsdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.47 |
| Current Ratio | 1.59 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.56 |
| Day Low | 7.38 |
| Debt To Equity | 79.532 |
| Earnings Call Timestamp End | 1,786,566,600 |
| Earnings Call Timestamp Start | 1,786,566,600 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | 1,216,000 |
| Ebitda Margins | 0.01783 |
| Enterprise To Ebitda | 173.301 |
| Enterprise To Revenue | 3.091 |
| Enterprise Value | 210,734,224 |
| Eps Forward | -0.06 |
| Eps Trailing Twelve Months | -0.22 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.82 |
| Fifty Day Average Change | 0.6499996 |
| Fifty Day Average Change Percent | 0.09530786 |
| Fifty Two Week Change Percent | 4.915726 |
| Fifty Two Week High | 9.555 |
| Fifty Two Week High Change | -2.0850005 |
| Fifty Two Week High Change Percent | -0.21821041 |
| Fifty Two Week Low | 4.31 |
| Fifty Two Week Low Change | 3.1599998 |
| Fifty Two Week Low Change Percent | 0.7331786 |
| Fifty Two Week Range | 4.31 - 9.555 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,636,727,400,000 |
| Float Shares | 15,592,849 |
| Forward Eps | -0.06 |
| Forward P E | -124.5 |
| Free Cashflow | -5,463,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 58 |
| Fullday Change | -0.0600004 |
| Fullday Change Percent | -0.796818 |
| Fullday Price | 7.56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.65450996 |
| Gross Profits | 44,625,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31753 |
| Held Percent Institutions | 0.48582 |
| Implied Shares Outstanding | 28,224,395 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,021-11-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. |
| Long Name | Journey Medical Corporation |
| Market | us_market |
| Market Cap | 210,836,240 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_280596341 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,104,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 212,529,694 |
| Number Of Analyst Opinions | 4 |
| Open | 7.56 |
| Operating Cashflow | -7,492,000 |
| Operating Margins | 0.02464 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 480 434 6670 |
| Post Market Change | 0.09000015 |
| Post Market Change Percent | 1.2048213 |
| Post Market Price | 7.56 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 7.53 |
| Price Hint | 2 |
| Price To Book | 6.4341083 |
| Price To Sales Trailing12 Months | 3.0923018 |
| Profit Margins | -0.08953 |
| Quick Ratio | 1.352 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0600004 |
| Regular Market Change Percent | -0.796818 |
| Regular Market Day High | 7.56 |
| Regular Market Day Low | 7.38 |
| Regular Market Day Range | 7.38 - 7.56 |
| Regular Market Open | 7.56 |
| Regular Market Previous Close | 7.53 |
| Regular Market Price | 7.47 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 122,960 |
| Return On Assets | -0.02095 |
| Return On Equity | -0.23768999 |
| Revenue Growth | 0.233 |
| Revenue Per Share | 2.552 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 22,224,395 |
| Shares Percent Shares Out | 0.1034 |
| Shares Short | 2,917,410 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,052,065 |
| Short Name | Journey Medical Corporation |
| Short Percent Of Float | 0.1841 |
| Short Ratio | 14.47 |
| Source Interval | 15 |
| State | AZ |
| Symbol | DERM |
| Target High Price | 15.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 13.75 |
| Target Median Price | 13.5 |
| Total Cash | 25,643,000 |
| Total Cash Per Share | 0.909 |
| Total Debt | 25,541,000 |
| Total Revenue | 68,181,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.9557 |
| Two Hundred Day Average Change | 0.51429987 |
| Two Hundred Day Average Change Percent | 0.07393934 |
| Type Disp | Equity |
| Volume | 122,960 |
| Website | https://journeymedicalcorp.com |
| Zip | 85,258 |